<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737501</url>
  </required_header>
  <id_info>
    <org_study_id>AP26113-13-301</org_study_id>
    <secondary_id>U1111-1210-4363</secondary_id>
    <secondary_id>2015-003447-19</secondary_id>
    <nct_id>NCT02737501</nct_id>
  </id_info>
  <brief_title>ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants</brief_title>
  <acronym>ALTA-1L</acronym>
  <official_title>A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in&#xD;
      ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to&#xD;
      ALK inhibitors, as evidenced by progression-free survival (PFS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase III, randomized, open-label, comparative, multicenter,&#xD;
      international study is to compare the efficacy and safety of brigatinib to that of crizotinib&#xD;
      in ALK+ locally advanced or metastatic NSCLC participants who have not previously been&#xD;
      treated with an ALK inhibitor. Participants will be stratified by the presence of CNS&#xD;
      metastases at baseline and prior chemotherapy used for locally advanced or metastatic&#xD;
      disease. Participants will be randomized in a 1:1 ratio to receive either brigatinib, 90 mg&#xD;
      orally once daily (QD) for 7 days, then a 180 mg orally QD, or crizotinib, 250 mg orally&#xD;
      twice daily (BID). Participants will receive treatment until disease progression, intolerable&#xD;
      toxicity, consent withdrawal, or death. Crossover from crizotinib to brigatinib is also&#xD;
      permitted.&#xD;
&#xD;
      The total estimated duration of the study is at least 4.5 years, including 1.5 years to&#xD;
      accrue participants, with at least 3 years for treatment and follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2016</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">July 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to end of study (Up to 56 months)</time_frame>
    <description>PFS as assessed by Blinded Independent Review Committee (BIRC), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, was defined as the time interval from the date of randomization until the date of the first documented PD event. The data was censored for participants without a PFS event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
    <description>ORR was defined as percentage of participants who achieved Complete response (CR) or Partial responses (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1 criteria. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to less than (&lt;) 10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Intracranial ORR (iORR)</measure>
    <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
    <description>ORR was defined as percentage of participants who achieved CR or PR in the central nervous system (CNS) in randomized participants with intracranial CNS metastasis at baseline. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Progression Free Survival</measure>
    <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
    <description>Intracranial PFS as assessed by BIRC, is defined as the time from randomization until first CNS PD is documented, or death due to any cause. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
    <description>Duration of response as assessed by BIRC, is defined as the time interval from the date that the criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease (PD) is objectively documented. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30 % decrease in the SLD of target lesions, taking as reference the baseline sum diameters. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and for non-target lesions, unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
    <description>Time to response as assessed by BIRC, assessment and is defined as the time interval from the date of randomization until the initial observation of CR or PR. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
    <description>Disease control as assessed by BIRC, defined as percentage of randomized participants who have achieved CR, PR, or stable disease (SD) after randomization. CR defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR: at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: SLD increased by at least 20% from the smallest value on study, SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose up to 30 days after last dose of study drug (Up to approximately 37 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug (i.e., occurs after the first dose of study drug) is also an AE. TEAEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of 30 days after the last dose of the treatment to which the participant was assigned, or the day before start of brigatinib therapy in crossover participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Health Status/Quality of Life as Assessed by EORTC QLQ-C30 (Version 3.0)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>HRQoL: perceived quality of participant's life, includes self-reported multidimensional measures of physical and mental health. Patient-reported symptoms (PROs) and HRQoL will be collected by administering the european organisation for research and treatment of cancer (EORTC) quality of life (QLQ)-C30 questionnaire. EORTC-QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. The 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into overall score ranging from 0 to 100, where lower scores indicate better QOL. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Advanced Malignancies</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Randomized Phase: Brigatinib 90 mg QD/180 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Phase: Crizotinib 250 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brigatinib</intervention_name>
    <description>Brigatinib tablets</description>
    <arm_group_label>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</arm_group_label>
    <arm_group_label>Randomized Phase: Brigatinib 90 mg QD/180 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib tablets</description>
    <arm_group_label>Randomized Phase: Crizotinib 250 mg BID</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for&#xD;
             definitive multimodality therapy) or stage four (IV) NSCLC.&#xD;
&#xD;
          2. Must have documented ALK rearrangement.&#xD;
&#xD;
          3. Have sufficient tumor tissue available for central analysis.&#xD;
&#xD;
          4. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.&#xD;
&#xD;
          5. Recovered from toxicities related to prior anticancer therapy to National Cancer&#xD;
             Institute (of the United States) (NCI) Common Terminology Criteria for Adverse Events&#xD;
             (version 4.0) (CTCAE v 4.0) grade be less than or equal to (&lt;=) 1.&#xD;
&#xD;
          6. Are a male or female participants greater than or equal to (&gt;=)18 years old.&#xD;
&#xD;
          7. Have adequate organ function, as defined by the study protocol.&#xD;
&#xD;
          8. Have Eastern Cooperative Oncology Group (ECOG) performance status &lt;=2.&#xD;
&#xD;
          9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected&#xD;
             (Fridericia) (QTcF) of &lt;= 450 millisecond (msec) in males or &lt;=470 msec in females.&#xD;
&#xD;
         10. For female participants of childbearing potential, have a negative pregnancy test&#xD;
             documented prior to randomization.&#xD;
&#xD;
         11. For female and male participants who are fertile, agree to use a highly effective form&#xD;
             of contraception, as defined by the study protocol.&#xD;
&#xD;
         12. Provide signed and dated informed consent indicating that the participants has been&#xD;
             informed of all pertinent aspects of the study, including the potential risks, and is&#xD;
             willingly participating.&#xD;
&#xD;
         13. Have the willingness and ability to comply with scheduled visit and study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received an investigational antineoplastic agent for NSCLC.&#xD;
&#xD;
          2. Previously received any prior tyrosine kinase inhibitor (TKI), including ALK-targeted&#xD;
             TKIs.&#xD;
&#xD;
          3. Previously received more than 1 regimen of systemic anticancer therapy for locally&#xD;
             advanced or metastatic disease.&#xD;
&#xD;
          4. Received chemotherapy or radiation within 14 days of first dose of study drug, except&#xD;
             stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).&#xD;
&#xD;
          5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of&#xD;
             study drug.&#xD;
&#xD;
          6. Had major surgery within 30 days of the first dose of study drug, minor surgical&#xD;
             procedures such as catheter placement or minimally invasive biopsies are allowed.&#xD;
&#xD;
          7. Have been diagnosed with another primary malignancy other than NSCLC, except for&#xD;
             adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively&#xD;
             treated non-metastatic prostate cancer; or participants with another primary&#xD;
             malignancy who are definitively relapse-free with at least 3 years elapsed since the&#xD;
             diagnosis of the other primary malignancy.&#xD;
&#xD;
          8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or&#xD;
             asymptomatic disease requiring an increasing dose of corticosteroids to control&#xD;
             symptoms within 7 days prior to randomization.&#xD;
&#xD;
          9. Have current spinal cord compression (symptomatic or asymptomatic and detected by&#xD;
             radiographic imaging). Participants with leptomeningeal disease and without cord&#xD;
             compression are allowed.&#xD;
&#xD;
         10. Be pregnant, planning a pregnancy, or breastfeeding.&#xD;
&#xD;
         11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the&#xD;
             study protocol.&#xD;
&#xD;
         12. Have uncontrolled hypertension.&#xD;
&#xD;
         13. Have a history or the presence at baseline of pulmonary interstitial disease,&#xD;
             drug-related pneumonitis, or radiation pneumonitis.&#xD;
&#xD;
         14. Have an ongoing or active infection.&#xD;
&#xD;
         15. Have a known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or&#xD;
             crizotinib or its excipients.&#xD;
&#xD;
         17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.&#xD;
&#xD;
         18. Have any condition or illness that, in the opinion of the investigator, would&#xD;
             compromise participant's safety or interfere with the evaluation of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USOR - Arizona Oncology Associates - Sedona</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Bellflower Medical Offices</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303-1385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care - Blue Ash</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242-5665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Fairfax Office</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Bentleigh East</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinium St. Polten</name>
      <address>
        <city>Sankt Polten</city>
        <state>Lower Austria</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Wagner-Spital Baumgartner Hohe</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Francois Baclesse</name>
      <address>
        <city>CAEN Cedex 5</city>
        <state>Basse-normandie</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Haute-normandie</state>
        <zip>76041</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <state>Ile-de-france</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-france</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hopital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <state>Provence Alpes COTE D'azur</state>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Michallon</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <state>Rhone-alpes</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-alpes</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koeln gGmbH - Krankenhaus Merheim</name>
      <address>
        <city>Koln</city>
        <state>Nordrhein-westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Haemato-Onkologie Hamburg Prof. Laack und Partner</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Tuen Mun</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kowloon</city>
        <zip>150001</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli-cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico di Bari Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Napoli Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg - Hopital Municipal</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis - Locatie Langendijk Breda</name>
      <address>
        <city>Breda</city>
        <state>Noord-brabant</state>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoCare Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera - Materno Infantil</name>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya Malaga Instituto de Neurociencias Clinicas</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University</name>
      <address>
        <city>Tainan</city>
        <state>Taipei</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and Saint Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>July 27, 2021</results_first_submitted>
  <results_first_submitted_qc>July 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Epithelial lung cancer</keyword>
  <keyword>Squamous cell carcinoma</keyword>
  <keyword>Large cell carcinoma</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Anaplastic Lymphoma Kinase (ALK)</keyword>
  <keyword>Advanced Cancers</keyword>
  <keyword>Brigatinib</keyword>
  <keyword>AP26113</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02737501/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02737501/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 92 investigative sites in Australia, Hong Kong, Singapore, South Korea, Taiwan, Austria, Denmark, France, Germany, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, Canada, and the United States of America from 26 May 2016 to 29 January 2021.</recruitment_details>
      <pre_assignment_details>Participants with anaplastic lymphoma kinase and non-small-cell lung cancer (ALK+ NSCLC) who had not previously received an ALK-targeted tyrosine kinase inhibitor (TKI) were enrolled in 1:1 ratio to receive brigatinib 90 mg for 7 days followed by 180 mg or crizotinib 250 mg. Participants from crizotinib arm who experienced progressive disease (PD) or received radiotherapy to the brain in Randomized Phase were crossed over to receive brigatinib 90 mg/180 mg in the Crossover Phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
          <description>Brigatinib 90 mg, tablets, orally, once daily (QD) for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until disease progression (PD), intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
        </group>
        <group group_id="P2">
          <title>Randomized Phase: Crizotinib 250 mg BID</title>
          <description>Crizotinib 250 mg, tablets, twice daily (BID) in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
        </group>
        <group group_id="P3">
          <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
          <description>Participants who experienced PD as assessed by the blinded Independent Review Committee (BIRC) or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Died</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Died</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
      <group_list>
        <group group_id="B1">
          <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
          <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
        </group>
        <group group_id="B2">
          <title>Randomized Phase: Crizotinib 250 mg BID</title>
          <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="13.46"/>
                    <measurement group_id="B2" value="58.6" spread="11.42"/>
                    <measurement group_id="B3" value="58.2" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic, Latino or Spanish</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic, Latino or Spanish</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic Of</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province Of China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luxembourg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="137"/>
                    <count group_id="B2" value="138"/>
                    <count group_id="B3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Global Health Status/Quality of Life (QoL)</title>
          <description>HRQoL:perceived quality of participant's life,includes self-reported multidimensional measures of physical,mental health.EORTC-QLQ-C30 contains 30 items across 5 functional scales(physical,role,cognitive,emotional,social),9 symptom scales(fatigue,nausea and vomiting,pain,dyspnea,sleep disturbance,appetite loss,constipation,diarrhea,financial difficulties),a global health status/QOL scale on 4 response levels(not at all,a little,quite a bit,very much),with 2 questions relying on a 7-point numeric rating scale.Raw scores converted into overall score of 0-100,lower scores indicate better QOL.</description>
          <population>Number analyzed is number of participants with data available for global health status/QoL at Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="131"/>
                    <count group_id="B2" value="131"/>
                    <count group_id="B3" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.432" lower_limit="0.00" upper_limit="100.00"/>
                    <measurement group_id="B2" value="59.160" lower_limit="0.00" upper_limit="100.00"/>
                    <measurement group_id="B3" value="59.796" lower_limit="0.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS as assessed by Blinded Independent Review Committee (BIRC), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, was defined as the time interval from the date of randomization until the date of the first documented PD event. The data was censored for participants without a PFS event.</description>
        <time_frame>Up to end of study (Up to 56 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS as assessed by Blinded Independent Review Committee (BIRC), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, was defined as the time interval from the date of randomization until the date of the first documented PD event. The data was censored for participants without a PFS event.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.016" lower_limit="18.46" upper_limit="43.20"/>
                    <measurement group_id="O2" value="11.072" lower_limit="9.13" upper_limit="13.01"/>
                    <measurement group_id="O3" value="16.821" lower_limit="10.12" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values are from a log-rank test stratified by randomization stratification factors (current; presence of intracranial central nervous system (iCNS) metastases at baseline and prior chemotherapy for locally advanced or metastatic disease).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.481</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>The hazard ratio was obtained using a Cox proportional hazards model with randomization stratification factors (current) as covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Objective Response Rate (ORR)</title>
        <description>ORR was defined as percentage of participants who achieved Complete response (CR) or Partial responses (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1 criteria. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to less than (&lt;) 10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters.</description>
        <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Objective Response Rate (ORR)</title>
          <description>ORR was defined as percentage of participants who achieved Complete response (CR) or Partial responses (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1 criteria. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to less than (&lt;) 10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" lower_limit="66.30" upper_limit="81.52"/>
                    <measurement group_id="O2" value="62.3" lower_limit="53.68" upper_limit="70.42"/>
                    <measurement group_id="O3" value="56.9" lower_limit="44.04" upper_limit="69.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0330</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
            <estimate_desc>Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of intracranial central nervous system (iCNS) metastases at Baseline, and prior chemotherapy for locally advanced or metastatic disease (current strata).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Intracranial ORR (iORR)</title>
        <description>ORR was defined as percentage of participants who achieved CR or PR in the central nervous system (CNS) in randomized participants with intracranial CNS metastasis at baseline. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Intracranial ORR (iORR)</title>
          <description>ORR was defined as percentage of participants who achieved CR or PR in the central nervous system (CNS) in randomized participants with intracranial CNS metastasis at baseline. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="50.69" upper_limit="79.14"/>
                    <measurement group_id="O2" value="14.3" lower_limit="5.94" upper_limit="27.24"/>
                    <measurement group_id="O3" value="35.7" lower_limit="21.55" upper_limit="51.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>13.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.70</ci_lower_limit>
            <ci_upper_limit>39.11</ci_upper_limit>
            <estimate_desc>Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of prior chemotherapy for Locally advanced or metastatic disease at study entry (current strata).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracranial Progression Free Survival</title>
        <description>Intracranial PFS as assessed by BIRC, is defined as the time from randomization until first CNS PD is documented, or death due to any cause. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
        <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Intracranial Progression Free Survival</title>
          <description>Intracranial PFS as assessed by BIRC, is defined as the time from randomization until first CNS PD is documented, or death due to any cause. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.951" lower_limit="12.91" upper_limit="30.78"/>
                    <measurement group_id="O2" value="5.520" lower_limit="3.71" upper_limit="7.52"/>
                    <measurement group_id="O3" value="24.542" lower_limit="12.58" upper_limit="NA">Upper limit of 95% confidence interval (CI) was not estimable due to low number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values are from a log-rank test stratified by randomization stratification factors (current; presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.293</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>The hazard ratio was obtained using a Cox proportional hazards model with prior chemotherapy for locally advanced or metastatic disease (current strata) as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
        <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to fewer number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to fewer number of participants with events.</measurement>
                    <measurement group_id="O3" value="35.023" lower_limit="30.42" upper_limit="NA">Upper limit of 95% CI was not estimable due to fewer number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>Duration of response as assessed by BIRC, is defined as the time interval from the date that the criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease (PD) is objectively documented. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30 % decrease in the SLD of target lesions, taking as reference the baseline sum diameters. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and for non-target lesions, unequivocal progression of existing non-target lesions.</description>
        <time_frame>Baseline up to end of study (Up to 56 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Only responders were reported for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>Duration of response as assessed by BIRC, is defined as the time interval from the date that the criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease (PD) is objectively documented. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30 % decrease in the SLD of target lesions, taking as reference the baseline sum diameters. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and for non-target lesions, unequivocal progression of existing non-target lesions.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Only responders were reported for this outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.150" lower_limit="1.84" upper_limit="50.60"/>
                    <measurement group_id="O2" value="13.832" lower_limit="1.45" upper_limit="49.81"/>
                    <measurement group_id="O3" value="19.154" lower_limit="1.97" upper_limit="33.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (TTR)</title>
        <description>Time to response as assessed by BIRC, assessment and is defined as the time interval from the date of randomization until the initial observation of CR or PR. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Only responders were reported for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (TTR)</title>
          <description>Time to response as assessed by BIRC, assessment and is defined as the time interval from the date of randomization until the initial observation of CR or PR. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Only responders were reported for this outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.840" lower_limit="1.02" upper_limit="29.47"/>
                    <measurement group_id="O2" value="1.873" lower_limit="0.79" upper_limit="7.43"/>
                    <measurement group_id="O3" value="1.873" lower_limit="0.20" upper_limit="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>Disease control as assessed by BIRC, defined as percentage of randomized participants who have achieved CR, PR, or stable disease (SD) after randomization. CR defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR: at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: SLD increased by at least 20% from the smallest value on study, SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
        <time_frame>Baseline up to end of treatment (Up to 36 months)</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>Disease control as assessed by BIRC, defined as percentage of randomized participants who have achieved CR, PR, or stable disease (SD) after randomization. CR defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (&lt;10 mm short axis), normalization of tumor marker level for non-target lesions. PR: at least a 30% decrease in SLD of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: SLD increased by at least 20% from the smallest value on study, SLD must also demonstrate an absolute increase of at least 5 mm, and unequivocal progression of existing non-target lesions.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="78.36" upper_limit="90.85"/>
                    <measurement group_id="O2" value="86.2" lower_limit="79.34" upper_limit="91.50"/>
                    <measurement group_id="O3" value="73.8" lower_limit="61.46" upper_limit="83.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8220</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
            <estimate_desc>Odds ratios and p-values were from a Cochran-Mantel-Haenszel test stratified by presence of iCNS metastases at Baseline, and prior chemotherapy for locally advanced or metastatic disease (current strata).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug (i.e., occurs after the first dose of study drug) is also an AE. TEAEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of 30 days after the last dose of the treatment to which the participant was assigned, or the day before start of brigatinib therapy in crossover participant.</description>
        <time_frame>From first dose up to 30 days after last dose of study drug (Up to approximately 37 months)</time_frame>
        <population>Treated Population included all participant who received at least 1 dose of study drug and served as basis of safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
          <group group_id="O3">
            <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
            <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug (i.e., occurs after the first dose of study drug) is also an AE. TEAEs are defined as AEs starting/worsening on or after the first dose of study treatment and no later than the earliest of 30 days after the last dose of the treatment to which the participant was assigned, or the day before start of brigatinib therapy in crossover participant.</description>
          <population>Treated Population included all participant who received at least 1 dose of study drug and served as basis of safety analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Health Status/Quality of Life as Assessed by EORTC QLQ-C30 (Version 3.0)</title>
        <description>HRQoL: perceived quality of participant's life, includes self-reported multidimensional measures of physical and mental health. Patient-reported symptoms (PROs) and HRQoL will be collected by administering the european organisation for research and treatment of cancer (EORTC) quality of life (QLQ)-C30 questionnaire. EORTC-QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. The 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into overall score ranging from 0 to 100, where lower scores indicate better QOL. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
            <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Phase: Crizotinib 250 mg BID</title>
            <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Health Status/Quality of Life as Assessed by EORTC QLQ-C30 (Version 3.0)</title>
          <description>HRQoL: perceived quality of participant's life, includes self-reported multidimensional measures of physical and mental health. Patient-reported symptoms (PROs) and HRQoL will be collected by administering the european organisation for research and treatment of cancer (EORTC) quality of life (QLQ)-C30 questionnaire. EORTC-QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. The 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into overall score ranging from 0 to 100, where lower scores indicate better QOL. A negative change from Baseline indicates improvement.</description>
          <population>ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed are the participants with data available for analyses.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.007" spread="25.7563"/>
                    <measurement group_id="O2" value="-4.088" spread="27.4748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0295</p_value>
            <p_value_desc>p-values were obtained using mixed effects models stratified by presence of iCNS metastases at study entry, prior chemotherapy at Baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed effect model is used with an unstructured covariance matrix.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>5.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>11.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality - Up to 56 months; Serious and other adverse events - From first dose up to 30 days after last dose of study drug (Up to approximately 37 months)</time_frame>
      <desc>All Cause-mortality: ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Serious and other (Non-serious): Treated Population included all participants who received 1 dose of study drug and served as basis of safety analysis. Crossover Population included participants from 'Crizotinib 250 mg BID' who crossed over to brigatinib following BIRC-assessed PD.</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized Phase: Brigatinib 90 mg QD/180 QD</title>
          <description>Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).</description>
        </group>
        <group group_id="E2">
          <title>Randomized Phase: Crizotinib 250 mg BID</title>
          <description>Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).</description>
        </group>
        <group group_id="E3">
          <title>Crossover Phase: Brigatinib 90 mg QD/180 mg QD</title>
          <description>Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anaemia Macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutropenic Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oesophageal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oesophagitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Drug-Induced Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pleural Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinusitis Fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Covid-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Salmonella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Brain Herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Transaminases Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm Progression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Metastases To Meninges</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Malignant Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Metastases To Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cancer Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Invasive Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer Stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma Of Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hodgkins Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tumour Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Intracranial Tumour Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vocal Cord Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Central Nervous System Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Depressed Level Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Generalised Tonic-Clonic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Intraventricular Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Qt Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood Insulin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Taste Disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dermatitis Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>TrialDisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

